Form 4: Compass Therapeutics Executive Acquires 20,000 Shares
SEC Form 4
Jonathan Anderman, General Counsel & Corporate Secretary of Compass Therapeutics, purchased 20,000 shares of common stock at $1.54 per share on April 7, 2025.
Summary
- On April 7, 2025, Jonathan Anderman, the General Counsel & Corporate Secretary of Compass Therapeutics, Inc. (CMPX), acquired 20,000 shares of common stock.
- The purchase price was $1.54 per share.
- Following the transaction, Anderman directly owns 21,000 shares of Compass Therapeutics.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. An insider purchase is generally viewed as a positive sign, but the scale of the purchase is relatively small.
Positives
- An executive's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/07/2025 | Date of the transaction: Jonathan Anderman purchased 20,000 shares of Compass Therapeutics common stock. |
| 04/08/2025 | Date of signature on the Form 4 filing. |
Keywords
Compass Therapeutics, CMPX, insider trading, Form 4, stock purchase, Jonathan Anderman, General Counsel, Corporate Secretary, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.